Clinical Significance of Antibodies to Ro52/TRIM21 in Systemic Sclerosis PDF Print E-mail
Thursday, 08 March 2012 09:27
Marie Hudson, Janet Pope, Michael Mahler, Solene Tatibouet, Russell Steele, Murray Baron, Canadian Scleroderma Research Group (csrg) and Marvin J Fritzler
Arthritis Research & Therapy 2012, 14:R50 doi:10.1186/ar3763
Published: 6 March 2012

Introduction
Autoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We undertook this study to determine clinical and serological associations of anti-Ro52/TRIM21 antibodies in patients with systemic sclerosis (SSc).

Methods
Detailed clinical data and sera from 963 patients with SSc enrolled in a multi-centre cohort study were collected and entered into a central database. Antibodies to Ro52/TRIM21 and other autoantibodies were detected by an addressable laser bead immunoassay and different enzyme-linked immunosorbent assay (ELISA) systems. Associations between anti-Ro52/TRIM21 antibodies and clinical and other serological manifestations of SSc were investigated.

Results
Anti-Ro52/TRIM21 antibodies were present in 20% of SSc patients and overlapped with other main SSc-related antibodies, including anti-centromere (by immunofluorescence and centromere protein (CENP)-A and CENP-B ELISA), anti-topoisomerase I, anti-RNA polymerase III and anti-Pm/Scl antibodies. Anti-Ro52/TRIM21 antibodies were strongly associated with interstitial lung disease (odds ratio (OR) 1.53, 95% confidence interval (CI) 1.11, 2.12, p=0.0091) and overlap syndrome (OR 2.06, 95% CI 1.01, 4.19, p=0.0059).

Conclusions
Anti-Ro52/TRIM21 antibodies were the second most common autoantibody in this SSc cohort. In SSc, anti-Ro52/TRIM21 antibodies may be a marker of interstitial lung disease and overlap syndrome.

The complete article is available below as a provisional PDF.

 
More articles :

» Pain Common in Systemic Sclerosis

Pain is common and can be severe in patients with systemic sclerosis, a cross-sectional analysis found.Among patients enrolled in the multicenter Canadian Scleroderma Research Group Registry, 83% experienced pain, more than one-third of them...

» Scleroderma Study Identifies Roadblocks To Employment

In the United States, the work disability rate for people with , also known as systemic sclerosis, is two to three times that of people with some other rheumatic conditions, according to research data from investigators at The (UTHealth) Medical...

» New Research Finds Pattern For Detecting 'False-positive' ANA Results

The presence of antinuclear antibodies (ANA) indicates the possibility of and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive"...

» Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies

Jessica Gordon and Robert SpieraReceived 1 June 2011; Revised 2 August 2011; Accepted 2 August 2011Systemic sclerosis (SSc) is a heterogeneous, multisystem disorder characterized by vasculopathy, fibrosis, and autoimmunity in the context of both...

» Erectile Dysfunction Drug Could Improve Raynaud’s Symptoms Associated with Scleroderma

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with can improve ’s phenomenon symptoms and heal and prevent hand and finger associated with it, according to research presented this week at the American College of Rheumatology...

» Causes Found for Stiff Skin Conditions

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about , a condition affecting about one in 5,000 people that leads to hardening of the...